Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 2/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666505 | 1.00 | SLC7A5 (0.48) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL664075 | 1.00 | SLC7A5 (0.48) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8871238 | 1.00 | SLC7A5 (0.48) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7453161 | 0.83 | RNPEP (0.48) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17283387 | 0.82 | SLC7A5 (0.48) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3686597 | 0.78 | SLC1A3 (0.43) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15980616 | 0.78 | SLC1A3 (0.43) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15980617 | 0.78 | SLC1A3 (0.43) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8872304 | 0.77 | MMP1 (0.51) | ANPEP | |
| SCHEMBL8872299 | 0.77 | MMP1 (0.51) | ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156732-A | A kind of synthetic method of optical voidness (R) -3- carbamoylmethyl -5- methylhexanoic acid | 安徽东凯生物科技有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-105175276-A | Synthetic method for optically pure(R)-3-carbamyl methyl-5-methyl caproic acid | EASTSKY PHARM ANHUI TECHNOLOGY CO LTD | 2015-12-23 | — | — | CN | claimed |
| CN-114686465-B | Synthesis method of hydrolase and (R) - (-) -3- (carbamoylmethyl) -5-methylhexanoic acid | 宁波酶赛生物工程有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114686465-A | Method for synthesizing hydrolase and (R) - (-) -3- (carbamoylmethyl) -5-methylhexanoic acid | 宁波酶赛生物工程有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110156732-A | A kind of synthetic method of optical voidness (R) -3- carbamoylmethyl -5- methylhexanoic acid | 安徽东凯生物科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110156732-A | A kind of synthetic method of optical voidness (R) -3- carbamoylmethyl -5- methylhexanoic acid | 安徽东凯生物科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110156732-A | A kind of synthetic method of optical voidness (R) -3- carbamoylmethyl -5- methylhexanoic acid | 安徽东凯生物科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-109970541-A | A kind of preparation method of pregabalin intermediate (R) -3- carbamoyhnethyl -5- methylhexanoic acid | 南京方生和医药科技有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-105175276-A | Synthetic method for optically pure(R)-3-carbamyl methyl-5-methyl caproic acid | EASTSKY PHARM ANHUI TECHNOLOGY CO LTD | 2015-12-23 | — | — | CN | disclosed |
| US-7563923-B2 | Prepared by decyclization and amidation of 3-isobutylglutaric anhydride with chiral 1-amino-1-arylalkane by dissolving amine in aromatic hydrocarbon, ether, halogenated hydrocarbon, alcohol, ester, alkane, or ketone solvent; cooling to +10 to -70 degrees C.; and reacting with anhydride | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-21 | — | — | US | disclosed |
| US-7470812-B2 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-30 | — | — | US | disclosed |
| US-7465826-B2 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-16 | — | — | US | disclosed |
| US-20080051602-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | KANSAL VINOD K | 2008-02-28 | — | — | US | disclosed |
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | KANSAL VINOD K | 2008-02-21 | — | — | US | disclosed |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL USA, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1802568-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007035789-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | GABRE, GABRA5, GABRA6 | SLC7A5 819/4885RNPEP 3729/4885SLC1A3 83/4885 |
| US-20080051602-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | GABRE, GABRA5, GABRA6 | SLC7A5 819/4885RNPEP 3729/4885SLC1A3 83/4885 |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | GABRE, GABRA5, GABRA6 | SLC7A5 819/4885RNPEP 3729/4885SLC1A3 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.